|1.||Kang, Sohye: 3 articles (11/2006 - 05/2002)|
|2.||Davis, Roger A: 3 articles (11/2006 - 05/2002)|
|3.||Spann, Nathanael J: 2 articles (11/2006 - 08/2003)|
|4.||Davis, R A: 2 articles (07/2000 - 06/2000)|
|5.||Wang, S L: 2 articles (07/2000 - 06/2000)|
|6.||Hoedemakers, Rein M J: 1 article (06/2014)|
|7.||Te Velthuis, Henk: 1 article (06/2014)|
|8.||Jacobs, Joannes F M: 1 article (06/2014)|
|9.||Teunissen, Elisa: 1 article (06/2014)|
|10.||Gao, Jinsong: 1 article (01/2014)|
04/01/2008 - "All "small" tumors (L<35 mm or V<11 cm(3)) were good outcome with 100% sensitivity but a rather low specificity (36% and 43% for L and V, respectively). "
11/15/1986 - "L-35 and L-36 were expressed on interleukin 2 (IL 2)-dependent cloned T cell lines, and were weakly expressed on the T cell tumor line, HSB-2. "
|2.||Hypertension (High Blood Pressure)
01/27/1997 - "Compared with runners who ran less than 16 km (10 miles) per week, long-distance runners (> or = 80 km/wk) showed an 85% reduced prevalence of high-density lipoprotein cholesterol levels that were clinically low (< 0.9 mmol/L [< 35 mg/dL]), a 2.5-fold increased prevalence of clinically defined high levels of high-density lipoprotein cholesterol (ie, > or = 1.55 mmol/L [> or = 60 mg/dL], the level thought to be protective against CHD), a nearly 50% reduction in hypertension, and more than a 50% reduction in the use of medications to lower blood pressure and plasma cholesterol levels. "
08/21/1996 - "The relative risk (RR) estimates (with 95% confidence intervals [CIs]) for premature CHD derived from a proportional hazards model that included age, body mass index, and the dichotomized risk factor covariables elevated plasma Lp(a) level, total cholesterol level of 6.2 mmol/L (240 mg/dL) or more, high-density lipoprotein (HDL) level less than 0.9 mmol/L (35 mg/dL), smoking, glucose intolerance, and hypertension were as follows: elevated Lp(a) level, RR, 1.9 (95% CI, 1.2-2.9), prevalence, 11.3%; total cholesterol level of 6.2 mmol/L or more, RR, 1.8 (95% CI, 1.2-2.7), prevalence, 14.3%; HDL level of less than 0.9 mmol/L, RR, 1.8 (95% CI, 1.2-2.6), prevalence 19.2%; smoking, RR 3.6 (95% CI, 2.2-5.5), prevalence, 46.7%; glucose intolerance, RR, 2.7 (95% CI, 1.4-5.3), prevalence, 2.6%; hypertension, RR, 1.2 (95% CI, 0.8-1.8), prevalence, 26.3%. "
|3.||Hepatocellular Carcinoma (Hepatoma)
04/15/1987 - "Previous pulse-chase studies with L-35 S methionine using the human hepatocellular carcinoma cell line, Hep-G2, showed that the three chains are not immediately disulfide-linked and that there exist intermediate precursors as well as pools of A alpha and gamma chains (J. "
03/01/1996 - "Rat hepatoma L35 cells, a liver-differentiated cell line, display resistance to bile acid repression of cholesterol 7 alpha-hydroxylase."
04/01/1991 - "Although parental hepatoma cells were all killed within a week, a 25-hydroxycholesterol-resistant cell line (L35 cells) which showed stable expression of 7-alpha-hydroxylase activity and mRNA was obtained. "
08/15/2003 - "Co-transfection studies show that ARP-1/COUP-TFII repressed MTP promoter activity by approximately 70% in FAO hepatoma cells, whereas RXRalpha and its ligand 9-cis-retinoic acid increased MTP promoter activity by 6-fold in L35 cells. "
07/01/2003 - "To identify proteins undergoing glutathionylation in primary rat hepatocytes and in human HepG2 hepatoma cells, we radiolabeled the intracellular GSH pool with L-[(35)S] cysteine. "
01/01/1967 - "1. In a study of the metabolism of l-[(35)S]methionine in vivo, the labelled sulphur compounds of rat liver and brain were separated first by ion-exchange chromatography into two fractions containing (i) free sulphur amino acids such as methionine, cystathionine, cyst(e)ine and homocyst(e)ine and (ii) glutathione. "
|5.||Renal Insufficiency (Renal Failure)
06/01/2014 - "In patients with renal failure, N Latex FLC detected higher concentrations of λFLC (CKD5 median, 128 mg/L; 95% range, 43-302) compared with Freelite (89.5 mg/L, 35-197) (p<0.0001). "
01/01/1994 - "Complications of ascites included: infection of ascitic liquid (35%), respiratory complications (65%), parietal complications (50%), consumption coagulopathy (35%), functional renal failure (Creat > 130 mumol/l, 35%). "
|4.||Messenger RNA (mRNA)
|5.||Eukaryotic Initiation Factors
|6.||Ribosomal Proteins (Ribosomal Protein)
|7.||Glutathione (Reduced Glutathione)